1. Home
  2. STEC vs MBRX Comparison

STEC vs MBRX Comparison

Compare STEC & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STEC
  • MBRX
  • Stock Information
  • Founded
  • STEC 2006
  • MBRX 2015
  • Country
  • STEC China
  • MBRX United States
  • Employees
  • STEC N/A
  • MBRX N/A
  • Industry
  • STEC
  • MBRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • STEC
  • MBRX Health Care
  • Exchange
  • STEC NYSE
  • MBRX Nasdaq
  • Market Cap
  • STEC 6.3M
  • MBRX 6.6M
  • IPO Year
  • STEC 2021
  • MBRX 2016
  • Fundamental
  • Price
  • STEC $1.59
  • MBRX $2.37
  • Analyst Decision
  • STEC
  • MBRX Strong Buy
  • Analyst Count
  • STEC 0
  • MBRX 3
  • Target Price
  • STEC N/A
  • MBRX $35.00
  • AVG Volume (30 Days)
  • STEC 4.5M
  • MBRX 47.4K
  • Earning Date
  • STEC 10-29-2024
  • MBRX 11-11-2024
  • Dividend Yield
  • STEC N/A
  • MBRX N/A
  • EPS Growth
  • STEC N/A
  • MBRX N/A
  • EPS
  • STEC N/A
  • MBRX N/A
  • Revenue
  • STEC $260,474,693.00
  • MBRX N/A
  • Revenue This Year
  • STEC $9.76
  • MBRX N/A
  • Revenue Next Year
  • STEC $15.85
  • MBRX N/A
  • P/E Ratio
  • STEC N/A
  • MBRX N/A
  • Revenue Growth
  • STEC N/A
  • MBRX N/A
  • 52 Week Low
  • STEC $0.20
  • MBRX $0.40
  • 52 Week High
  • STEC $7.38
  • MBRX $6.24
  • Technical
  • Relative Strength Index (RSI)
  • STEC 64.50
  • MBRX 44.84
  • Support Level
  • STEC $0.32
  • MBRX $2.30
  • Resistance Level
  • STEC $3.25
  • MBRX $2.63
  • Average True Range (ATR)
  • STEC 0.21
  • MBRX 0.18
  • MACD
  • STEC 0.16
  • MBRX -0.01
  • Stochastic Oscillator
  • STEC 43.38
  • MBRX 12.96

About STEC SANTECH HOLDINGS LIMITED

Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Share on Social Networks: